These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. Calati R; Crisafulli C; Balestri M; Serretti A; Spina E; Calabrò M; Sidoti A; Albani D; Massat I; Höfer P; Amital D; Juven-Wetzler A; Kasper S; Zohar J; Souery D; Montgomery S; Mendlewicz J Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jul; 44():271-8. PubMed ID: 23537502 [TBL] [Abstract][Full Text] [Related]
4. What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. Souery D; Calati R; Papageorgiou K; Juven-Wetzler A; Gailledreau J; Modavi D; Sentissi O; Pitchot W; Papadimitriou GN; Dikeos D; Montgomery S; Kasper S; Zohar J; Serretti A; Mendlewicz J World J Biol Psychiatry; 2015 Oct; 16(7):472-82. PubMed ID: 25535987 [TBL] [Abstract][Full Text] [Related]
5. Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response. Li QS; Tian C; Seabrook GR; Drevets WC; Narayan VA Transl Psychiatry; 2016 Sep; 6(9):e889. PubMed ID: 27622933 [TBL] [Abstract][Full Text] [Related]
6. Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. Olgiati P; Serretti A; Souery D; Dold M; Kasper S; Montgomery S; Zohar J; Mendlewicz J J Affect Disord; 2018 Feb; 227():777-786. PubMed ID: 29254066 [TBL] [Abstract][Full Text] [Related]
7. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. ; ; Am J Psychiatry; 2013 Feb; 170(2):207-17. PubMed ID: 23377640 [TBL] [Abstract][Full Text] [Related]
8. Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes. Altmann H; Stahl ST; Gebara MA; Lenze EJ; Mulsant BH; Blumberger DM; Reynolds CF; Karp JF J Clin Psychiatry; 2020 Sep; 81(6):. PubMed ID: 32991792 [TBL] [Abstract][Full Text] [Related]
9. Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression--The EMC trial. Tadić A; Wachtlin D; Berger M; Braus DF; van Calker D; Dahmen N; Dreimüller N; Engel A; Gorbulev S; Helmreich I; Kaiser AK; Kronfeld K; Schlicht KF; Tüscher O; Wagner S; Hiemke C; Lieb K Eur Neuropsychopharmacol; 2016 Apr; 26(4):705-16. PubMed ID: 26899588 [TBL] [Abstract][Full Text] [Related]
10. Usefulness of repetitive transcranial magnetic stimulation as a maintenance treatment in patients with major depression. Haesebaert F; Moirand R; Schott-Pethelaz AM; Brunelin J; Poulet E World J Biol Psychiatry; 2018 Feb; 19(1):74-78. PubMed ID: 27807990 [TBL] [Abstract][Full Text] [Related]
11. ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial. Schatzberg AF; DeBattista C; Lazzeroni LC; Etkin A; Murphy GM; Williams LM Am J Psychiatry; 2015 Aug; 172(8):751-9. PubMed ID: 25815420 [TBL] [Abstract][Full Text] [Related]
12. Early improvement predicts 8-week treatment outcome in patients with generalized anxiety disorder treated with escitalopram or venlafaxine. Qian M; Shen Z; Lin M; Guan T; Yang J; Li L; Shen X; Yuan Y Asia Pac Psychiatry; 2017 Dec; 9(4):. PubMed ID: 29193711 [TBL] [Abstract][Full Text] [Related]
13. Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. Balestri M; Calati R; Souery D; Kautzky A; Kasper S; Montgomery S; Zohar J; Mendlewicz J; Serretti A J Affect Disord; 2016 Jan; 189():224-32. PubMed ID: 26451508 [TBL] [Abstract][Full Text] [Related]
14. Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder. Dreimüller N; Wagner S; Engel A; Braus DF; Roll SC; Elsner S; Tadić A; Lieb K BMC Psychiatry; 2019 Jan; 19(1):24. PubMed ID: 30642308 [TBL] [Abstract][Full Text] [Related]
15. A genomewide association study of citalopram response in major depressive disorder. Garriock HA; Kraft JB; Shyn SI; Peters EJ; Yokoyama JS; Jenkins GD; Reinalda MS; Slager SL; McGrath PJ; Hamilton SP Biol Psychiatry; 2010 Jan; 67(2):133-8. PubMed ID: 19846067 [TBL] [Abstract][Full Text] [Related]
16. EEG Abnormalities Are Associated With Poorer Depressive Symptom Outcomes With Escitalopram and Venlafaxine-XR, but Not Sertraline: Results From the Multicenter Randomized iSPOT-D Study. Arns M; Gordon E; Boutros NN Clin EEG Neurosci; 2017 Jan; 48(1):33-40. PubMed ID: 26674366 [TBL] [Abstract][Full Text] [Related]